Balchem Corporation reported a strong third quarter in 2025, achieving record sales and profitability across all segments, marking the 25th consecutive quarter of year-over-year adjusted EBITDA growth.

• Consolidated sales and adjusted EBITDA reached record levels, driven by robust demand in Human Nutrition and Health products.
• Year-over-year growth was noted in all three reporting segments: Human Nutrition, Animal Nutrition and Health, and Specialty Products.
• The company successfully managed to offset the impact of tariffs through strategic supply chain adjustments and pricing actions.
• Balchem's scientific research initiatives continue to advance, with significant findings from the NIH-funded choline biomarker study promising to enhance the understanding of human choline deficiencies.
• Ongoing investments in marketing capabilities, including the Real Science Exchange platform, are expanding brand reach and engagement within the industry.